Benralizumab in eosinophilic granulomatosis with polyangiitis

Laorden, Daniel; Romero, David; Ortega, Javier Domínguez

doi:10.1016/j.medcli.2021.07.017

Cited by 5 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of EGPA is approximately 0.5-4.2 per million in the population[ 1 ]. It mainly affects people aged 40-60 years[ 9 ], but this patient was only 20 years old, making this a rare case. The etiology of this condition is unknown, although it may include environmental, genetic, and immune factors.…”

Section: Discussionmentioning

confidence: 99%

Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report

He,

Liu,

Zhang

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

In recent years, metabolomics research has become a hot spot in the screening and treatment of cancer. It is a popular technique for the quantitative characterization of small molecular compounds in biological cells, tissues, organs or organisms. Further study of the tumor revealed that amino acid changes may occur early in the tumor. The rapid growth and metabolism required for survival result in tumors exhibiting an increased demand for amino acids. An abundant supply of amino acids is important for cancer to maintain its proliferative driving force. Changes in amino acid metabolism can be used to screen malignant tumors and improve therapeutic outcomes. Therefore, it is particularly important to study the characteristics of amino acid metabolism in colorectal cancer. This article reviews several specific amino acid metabolism characteristics in colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report

He,

Liu,

Zhang

et al. 2023

World J Clin Cases

View full text Add to dashboard Cite

show abstract

“…Benralizumab has also been reported to improve cutaneous vasculitis ( Menzella et al, 2021 ) and cardiac and brain vasculitis ( Kolios et al, 2021 ) in EGPA. When used in EGPA benralizumab can nullify ANCA titers ( Kolios et al, 2021 ); ( Laorden et al, 2021 ) or decrease them ( Menzella et al, 2021 ; Miyata et al, 2021 ; Takenaka et al, 2019 ). Most patients in the aforementioned reports were diagnosed in the 5th decade of life, while one patient was diagnosed in the 3rd decade of life, in contrast with our patient who was diagnosed with EGPA at a much younger age.…”

Section: Discussionmentioning

confidence: 99%

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

et al. 2022

View full text Add to dashboard Cite

Background: Traditionally, Eosinophilic Granulomatosis with Polyangiitis (EGPA) has been treated with systemic corticosteroids and immunosuppressants. In recent years, therapeutic efforts have been directed towards targeting eosinophils which represent a major player in the pathogenesis of EGPA. In 2017 the Food and Drug Administration (FDA) approved mepolizumab, a humanized monoclonal antibody targeting interleukin 5 (IL-5) which reduces the production and survival of eosinophils, already used to treat severe eosinophilic asthma, for the management of EGPA. Benralizumab is a humanized monoclonal antibody that targets the IL-5 receptor and is indicated in the treatment of severe eosinophilic asthma.Case description: We describe the case of a young female with a positive history of severe eosinophilic asthma associated with EGPA, treated successfully with benralizumab.

show abstract

“…The use of biological therapies such as monoclonal antibodies has been described as useful in the treatment of this disease ( 122 ). In these patients, the use of anti-IL-5 drugs (mepolizumab, reslizumab), that bind circulating IL-5 ( 122 ), inhibits the maturation and differentiation of eosinophils, thereby decreasing their counts in peripheral blood and tissue ( 123 – 125 ). Furthermore, drugs targeting the IL-5 receptor, IL-5Rα, such as benralizumab, enhance the elimination of eosinophils and their precursors by antibody-dependent cellular cytotoxicity ( 124 , 126 ), with a correlation between the initial eosinophil counts and the response to some of these treatments ( 127 ).…”

Section: Treatment Of Eosinophil-associated Diseasesmentioning

confidence: 99%

Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach

et al. 2023

View full text Add to dashboard Cite

Elevated eosinophil counts in blood and tissue are a feature of many pathological processes. Eosinophils can migrate and accumulate in a wide variety of tissues and, by infiltrating a target organ, can mediate the development of several inflammatory diseases. The normalization of eosinophilia is a common biomarker of a treatable trait and can also be used as a prognostic and predictive biomarker since it implies a reduction in type 2 inflammation that contributes to disease pathogenesis. Biological therapies targeting this cell type and its proinflammatory mediators have been shown to be effective in the management of a number of eosinophilic diseases, and for this reason they constitute a potential common strategy in the treatment of patients with various multimorbidities that present with type 2 inflammation. Various biological options are available that could be used to simultaneously treat multiple target organs with a single drug, bearing in mind the need to offer personalized treatments under the umbrella of precision medicine in all patients with eosinophil-associated diseases (EADs). In addition to reviewing these issues, we also discuss a series of perspectives addressing the management of EAD patients from a multidisciplinary approach, with the collaboration of health professionals from different specialties who manage the different multimorbidities that frequently occur in these patients. We examine the basic principles of care that this multidisciplinary approach must cover and present a multidisciplinary expert opinion regarding the ideal management of patients with EADs, from diagnosis to therapeutic approach and follow-up.

show abstract

Benralizumab in eosinophilic granulomatosis with polyangiitis

Cited by 5 publications

References 4 publications

Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report

Eosinophilic granulomatosis with polyangiitis, asthma as the first symptom, and subsequent Loeffler endocarditis: A case report

Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab

Management of eosinophil-associated inflammatory diseases: the importance of a multidisciplinary approach

Contact Info

Product

Resources

About